Luxembourg Institute of Health

TL;DR

The lecture discusses personalized functional profiling for cancer treatment.

Transcript

e e e e e e e e e e e e e e e e for ah for presentation it's there for okay I displayer computer setting foree name ipk in of Kore IND accelerating pre medicine for cancer patients through personalized functional profiling thank you for the uh very nice introduction I'm honored to be uh sharing my research to uh uh a student in kore... Read More

Key Insights

• Luxembourg is strategically positioned in Europe, allowing for collaboration with various countries, including the US and Asia, in the health industry.
• The Luxembourg Institute of Health focuses on personalized medicine for cancer and other diseases, employing around 500 researchers.
• Traditional drug development is costly and lengthy, with low success rates, prompting the need for personalized medicine.
• Genomic-driven personalized treatments have limitations, with only a small percentage of patients benefiting significantly.
• Functional assessments are essential for bridging gaps in genomic data, leading to the development of personalized functional profiling.
• Organoid technology allows for the creation of personalized treatment options, enhancing the accuracy of drug response predictions.
• The platform developed uses patient-derived organoids to match drugs, offering insights into off-label drug use in countries like Luxembourg.
• Collaboration with biotech companies and integration of AI could further enhance personalized oncology models in the future.

Questions & Answers

Q: What is the strategic advantage of Luxembourg in the health industry?

Luxembourg's strategic advantage lies in its central location in Europe, bordering Belgium, Germany, and France. This positioning facilitates collaboration with European, Asian, and US partners in the health industry. Additionally, Luxembourg's high GDP and focus on economic diversification into health industries make it an attractive hub for medical research and innovation.

Q: What are the main focuses of the Luxembourg Institute of Health?

The Luxembourg Institute of Health focuses on developing personalized medicine for various diseases, including cancer, immune-related diseases, and neurodegenerative disorders. The institute aims to impact patient health positively by employing advanced technologies and research methodologies to create personalized treatment options, particularly through personalized functional profiling.

Q: Why is personalized medicine important in cancer treatment?

Personalized medicine is crucial in cancer treatment because traditional drug development is expensive, time-consuming, and often ineffective, with success rates as low as 5-10%. Personalized medicine aims to tailor treatments to individual patients based on their unique genetic and functional profiles, thereby increasing the likelihood of treatment success and reducing adverse effects.

Q: What limitations exist in genomic-driven personalized treatments?

Genomic-driven personalized treatments face limitations, as studies have shown that only a small percentage of patients benefit significantly. For example, a large retrospective study found that only 8% of patients were eligible for genomic-driven treatments, and only 4% could be cured. These limitations highlight the need for additional functional assessments to improve treatment accuracy.

Q: How does personalized functional profiling work?

Personalized functional profiling involves creating patient-derived organoids from tumor biopsies, which are then used to test various FDA-approved drugs. This method combines genomic sequencing and functional assessments to identify the most effective treatment options for individual patients, allowing for more accurate predictions of drug responses and personalized treatment strategies.

Q: What are the benefits of organoid technology in cancer treatment?

Organoid technology offers several benefits in cancer treatment, including the ability to model patient-specific tumor characteristics and test drug responses in a controlled environment. This approach enhances the precision of treatment predictions, allows for the exploration of off-label drug uses, and provides a platform for testing new drugs, potentially leading to more effective and personalized cancer therapies.

Q: How does the Luxembourg Institute of Health collaborate with biotech companies?

The Luxembourg Institute of Health collaborates with biotech companies like MBD to optimize platforms for personalized cancer treatment. These collaborations involve sharing expertise and resources to develop and test new methodologies, such as using patient-derived organoids for drug screening, ultimately aiming to improve treatment outcomes and advance personalized medicine.

Q: What future developments are anticipated in personalized oncology models?

Future developments in personalized oncology models may include integrating AI and machine learning algorithms to enhance drug response predictions. By combining clinical, genomic, and functional profiling data, these models could potentially predict treatment outcomes without the need for extensive drug screening. Such advancements would streamline personalized treatment processes and improve patient care.

Summary & Key Takeaways

• The Luxembourg Institute of Health is advancing personalized medicine, particularly for cancer patients, by developing personalized functional profiling. This approach uses patient-derived organoids to predict drug responses more accurately than traditional genomic methods.

• Luxembourg's strategic location and economic focus on health industries facilitate collaboration with global partners. The institute employs over 500 researchers dedicated to improving patient outcomes through innovative treatments.

• Challenges in traditional drug development, such as high costs and low success rates, highlight the need for personalized medicine. Functional assessments and organoid technology offer promising solutions, potentially revolutionizing cancer treatment.